bpc 157 pharmacokinetics half life study BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers High-level overview of pathways modulated
Description
An arthritogenic monoclonal antibody to type II collagen, CII-C1, impairs cartilage formation by cultured chondrocytes
Bryan Johnsons Peptide Philosophy Source: x.com/bryan_johnson Before any compound, Johnsons position is that the basics come first
Options include bringing cooler with ice packs, planning travel during off-cycle periods, or accepting gap in protocol
These bispecific constructs, characterized by their small size, high solubility and extended half-life facilitated by the integration of an albumin-specific sdAb, have demonstrated potent cytotoxicity against tumor cells, exceeding the ADCC of Daratumumab [94]
